Basimglurant sulfate

Synonyms: RG7090 sulfate; RO4917523 sulfate
Basimglurant (RG7090; RO4917523) sulfate 是一种选择性、口服有效且可穿透血脑屏障的代谢型谷氨酸受体 5 (mGluR5) 负性变构调节剂,对 [³H]-ABP688 (MS-T13256) 和 [³H]-MPEP (MS-X10413) 的 Ki 分别为 1.4 nM 和 35.6 nM,可抑制 mGlu5 介导的信号通路及受体组成型活性、调节伏隔核多巴胺水平,从而发挥抗焦虑、类抗抑郁、镇痛和促觉醒作用,并改变非快速眼动睡眠的 δ 波功率,可用于抑郁症、脆性 X 综合征、焦虑症等研究。
产品编号: MS-Y94289 CAS No.: 1034442-21-1 分子式: C18H15ClFN3O4S 分子量: 423.85
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

Basimglurant (RG7090; RO4917523) sulfate 是一种选择性、口服有效且可穿透血脑屏障的代谢型谷氨酸受体 5 (mGluR5) 负性变构调节剂,对 [³H]-ABP688 (MS-T13256) 和 [³H]-MPEP (MS-X10413) 的 Ki 分别为 1.4 nM 和 35.6 nM,可抑制 mGlu5 介导的信号通路及受体组成型活性、调节伏隔核多巴胺水平,从而发挥抗焦虑、类抗抑郁、镇痛和促觉醒作用,并改变非快速眼动睡眠的 δ 波功率,可用于抑郁症、脆性 X 综合征、焦虑症等研究。

生物实验数据

生物活性 Basimglurant (RG7090; RO4917523) sulfate is a selective, orally active, blood-brain barrier-penetrant negative allosteric modulator of metabotropic glutamate receptor 5 (mGluR5) with Ki values of 1.4 nM for [³H]-ABP688 (MS-T13256) and 35.6 nM for [³H]-MPEP (MS-X10413); it inhibits mGlu5-mediated signaling pathways and receptor constitutive activity, modulates accumbal dopamine levels, exerts anxiolytic, antidepressant-like, analgesic, and wake-promoting effects, and alters delta wave power during non-rapid eye movement sleep, and can be used for research on depression, fragile X syndrome, anxiety disorders, and other conditions.
体外研究
(In Vitro)

Basimglurant sulfate 在大鼠肝微粒体中代谢稳定性较低 (11 μL/min/mg),在人肝微粒体中稳定性良好 (CL <10 μL/min/mg)。
Basimglurant sulfate 在胚胎干细胞试验中无致畸潜力。
Basimglurant sulfate 可强效抑制 [3H]-MPEP 与人、小鼠及大鼠 mGlu5 受体的结合,其对三种受体的 Ki 值分别为 35.6 nM、29.5 nM 和 33.2 nM。
Basimglurant sulfate 可强效抑制人、小鼠和大鼠 mGlu5 表达型 HEK293 细胞中由使 Quisqualate 诱导的钙动员,其 IC50 值分别为 7.0 nM、8.88 nM 和 7.48 nM。
Basimglurant sulfate 可强效抑制 Quisqualate 诱导的表达人、小鼠和大鼠 mGlu5 的 HEK293 细胞中 IP 的积累,其 IC50 值分别为 5.85 nM、4.98 nM 和 5.93 nM;同时它可作为人 mGlu5 受体的反向激动剂,对应的 IC50 为 38.1 nM。

体内研究
(In Vivo)

Basimglurant (1-3 mg/kg;腹腔注射,每日给药,连续 21 天) sulfate 在慢性温和应激诱导快感缺失的大鼠中表现出显著的类抗抑郁活性。
Basimglurant (10-30 mg/kg;口服;24 小时内给药 3 次) sulfate 可在大鼠强迫游泳实验中产生类抗抑郁作用。
Basimglurant (1-30 mg/kg;口服;单次给药) sulfate 可在大鼠中诱导与典型抗抑郁药高度相似的脑活动模式。
Basimglurant (0.03-0.3 mg/kg;口服;单次给药) sulfate 在大鼠 Vogel 冲突试验中表现出类抗焦虑活性。
Basimglurant (0.01-1 mg/kg;口服;单次给药) sulfate 在小鼠应激诱导的体温过高试验中发挥抗焦虑作用。
Basimglurant (0.3-1 mg/kg;口服;单次给药) sulfate 在大鼠条件性情绪反应试验中表现出类抗焦虑活性。
Basimglurant (0.1-1 mg/kg;口服;单次给药) sulfate 在大鼠恐惧增强惊跳实验中产生类抗焦虑作用。
Basimglurant (10 mg/kg;口服;单次给药) sulfate 在小鼠福尔马林诱导疼痛模型的晚期阶段表现出镇痛活性。
Basimglurant (0.1-10 mg/kg;皮下注射;单次给药) sulfate 可剂量依赖性地抑制坐骨神经结扎大鼠的冷异常痛觉。
Basimglurant (0.03-0.3 mg/kg;静脉注射;单次给药) sulfate 可剂量依赖性地提高麻醉大鼠的排尿阈值容量。
Basimglurant (0.01-0.03 mg/kg;静脉注射;单次给药) sulfate 可强效降低麻醉大鼠的膀胱收缩频率。
basimglurant (0.03-0.3 mg/kg;口服;每日一次;连续 5 天) sulfate 可在挪威大鼠的活动暗期产生剂量依赖性的促觉醒作用,减少快速眼动 (REM) 睡眠和非快速眼动 (non-REM) 睡眠,延长睡眠潜伏期,并增强非快速眼动睡眠的 δ 波功率。

Animal Model: Wistar rats (male, 350 g, chronic mild stress-induced anhedonia model with unilateral ventral tegmental area electrode implantation)
Dosage: 1 mg/kg; 3 mg/kg
Administration: i.p.; daily; 21 days
Result: Reduced the anhedonia index by -72% (day 35), -53% (day 39), and -64% (day 42) compared to vehicle-treated stressed rats at 3 mg/kg, normalizing values to pre-stress baseline levels.
Reduced the anhedonia index significantly with consistent effects across the treatment period at 1 mg/kg.
Had no significant effect on anhedonia index in unstressed rats.
Animal Model: Wistar rats (female, 100-130 g, forced swim test model)
Dosage: 10 mg/kg; 30 mg/kg
Administration: p.o.; 3 doses over 24 hours (24 h, 16 h, 2 h pre-test)
Result: Reduced immobility time by -19% at 10 mg/kg and -16% at 30 mg/kg compared to vehicle-treated rats.
Animal Model: Fischer F344 rats (male, ~250 g, fMRI-based brain activity profiling model)
Dosage: 1 mg/kg; 10 mg/kg; 30 mg/kg
Administration: p.o.; single dose; 1 hour pre-fMRI imaging
Result: Increased perfusion in the dorsal striatum and decreased perfusion in the medial prefrontal cortex, dorsal hippocampus, thalamus, hypothalamus, septum, nucleus accumbens, ventral pallidum, and entorhinal piriform cortex at 1 mg/kg.
Amplified the perfusion changes observed at 1 mg/kg at 10 mg/kg.
Showed a pattern match coefficient (PMC) of >0.71 compared to prototypical antidepressants including duloxetine, reboxetine, imipramine, bupropion, and electroconvulsive treatment (ECT) at 1 and 10 mg/kg.
Surpassed the root mean square (RMS) response strength of ECT and standard antidepressants at 30 mg/kg at 1 and 10 mg/kg.
Animal Model: Sprague Dawley rats (male, 190-210 g, Vogel conflict drinking test model)
Dosage: 0.03 mg/kg; 0.1 mg/kg; 0.3 mg/kg
Administration: p.o.; single dose; 1 hour pre-test
Result: Increased punished drinking time by +165% at 0.03 mg/kg, with further increases at higher doses, reaching significance at all tested doses compared to vehicle.
Animal Model: NMRI mice (male, ~22 g, stress-induced hyperthermia model)
Dosage: 0.01 mg/kg; 0.1 mg/kg; 1 mg/kg
Administration: p.o.; single dose; 1 hour pre-test
Result: Reduced stress-induced hyperthermia by -48% at 0.01 mg/kg, -73% at 0.1 mg/kg, and -145% at 1 mg/kg compared to vehicle, with all doses producing significant effects.
Animal Model: Sprague Dawley rats (male, 350 g, conditioned emotional response model)
Dosage: 0.3 mg/kg; 1 mg/kg
Administration: p.o.; single dose; 1 hour pre-test
Result: Increased the suppression ratio by +567% at 0.3 mg/kg and +583% at 1 mg/kg compared to vehicle, indicating reduced fear response.
Animal Model: Sprague Dawley rats (male, 225-287 g, fear-potentiated startle model)
Dosage: 0.1 mg/kg; 1 mg/kg
Administration: p.o.; single dose; 1 hour pre-test
Result: Reduced fear-potentiated startle amplitude by -53% at 0.1 mg/kg and -94% at 1 mg/kg compared to vehicle, with significant effects at both doses.
Animal Model: NMRI mice (male, 24-30 g, formalin-induced paw licking model, late phase)
Dosage: 1 mg/kg; 10 mg/kg
Administration: p.o.; single dose; 40 minutes pre-formalin injection
Result: Reduced paw licking time by -91% (non-significant) at 1 mg/kg and -95% (significant) at 10 mg/kg compared to vehicle in the late phase of formalin-induced pain.
Had no significant effect in the early phase at any tested dose.
Animal Model: Sprague Dawley rats (female, 100-250 g, Bennett model of cold allodynia with sciatic nerve constriction injury)
Dosage: 0.1 mg/kg; 0.3 mg/kg; 1 mg/kg; 3 mg/kg; 10 mg/kg
Administration: s.c.; single dose; 60 minutes pre-test
Result: Increased the inhibition rate of cold allodynia by 28% at 0.1 mg/kg, 37% at 0.3 mg/kg, 50% at 1 mg/kg, 39% at 3 mg/kg, and 58% at 10 mg/kg compared to vehicle.
Produced significant effects at all doses, with maximal efficacy comparable to morphine (64% inhibition rate) and duloxetine (56% inhibition rate).
Animal Model: Sprague Dawley rats (female, 200-250 g, volume-induced micturition reflex model with cannulated bladders, anesthetized)
Dosage: 0.03 mg/kg; 0.3 mg/kg
Administration: i.v.; single dose
Result: Increased the micturition threshold volume by +27% at 0.03 mg/kg and +166.9% at 0.3 mg/kg compared to baseline, with significant effects at both doses.
Animal Model: Sprague Dawley rats (female, 200-250 g, isovolumetric bladder contraction model with cannulated bladders, anesthetized)
Dosage: 0.01 mg/kg; 0.03 mg/kg
Administration: i.v.; single dose
Result: Reduced bladder contraction frequency by -88.5% at 0.01 mg/kg and -79.9% at 0.03 mg/kg compared to vehicle, with maximal effects comparable at both doses.
Animal Model: Sprague Dawley rats (male, 275-325 g, telemetric EEG/EMG recording model in freely moving rats)
Dosage: 0.03 mg/kg; 0.1 mg/kg; 0.3 mg/kg
Administration: p.o.; daily; 5 days, administered at ZT 14
Result: Reduced the REM/non-REM sleep ratio during the dark phase by up to 67% at 0.3 mg/kg.
Reduced time spent in REM sleep by up to 100% (0.1 mg/kg) and non-REM sleep by up to 94% (0.1 mg/kg) during the dark phase.
Increased latency to REM sleep onset by up to +351% and non-REM sleep onset by up to +226% at 0.3 mg/kg.
Increased wakefulness by up to 136% (0.3 mg/kg) and locomotor activity by up to +200% (0.3 mg/kg) during the dark phase, with no subsequent hypersomnolence.
Increased delta power by up to +307% at 0.3 mg/kg during non-REM sleep in the dark phase, an effect that persisted into the light phase.

化学信息

分子量 423.85
分子式 C18H15ClFN3O4S
CAS No. 1034442-21-1
别名 RG7090 sulfate; RO4917523 sulfate

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础